Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01147458 · ClinicalTrials.gov registry record · Phase 2
A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 190
- Enrollment target
NCT01147458 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 190 participants.
The verdict
NCT01147458, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 190 participants
- Enrollment target
Study Summary
PF-04191834 works in animal models by inhibiting one of the enzymes, 5-lipoxygenasein which is involved in the pathway that causes inflammation and pain. The purpose of this study is to test how effective, safe and tolerated PF-04191834 is in patients with osteoarthritis of the knee by itself or with naproxen, particularly to test if patients have less pain.
Interventions
- DRUG PF-04191834
- DRUG PF-04191834 placebo
- DRUG Naproxen placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01147458
The ClinicalTrials.gov registry entry for NCT01147458 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 190 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PF-04191834 is the first listed.
NCT01147458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01147458 about?
NCT01147458 is a clinical study titled "A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee". PF-04191834 works in animal models by inhibiting one of the enzymes, 5-lipoxygenasein which is involved in the pathway that causes inflammation and pain. The purpose of this study is to test how effective, safe and tolerated PF-04191834 is in patients with osteoarthritis of the knee by itself or wit...
What is the current status of trial NCT01147458?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 190 participants. The study started on 2010-07. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01147458?
The interventions under investigation include: PF-04191834 (DRUG), PF-04191834 placebo (DRUG), Naproxen placebo (DRUG).
Who is sponsoring clinical trial NCT01147458?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.